Case Summary:

An expert in the field of biomedical engineering from Bangladesh came to us seeking help with his NIW (National Interest Waiver). He was a Ph.D. in integrative bioscience and was working as a senior scientist at that time. His proposed endeavor was to continue his research on the production of novel, targeted drug delivery options for cancer immunotherapy that improve patient outcomes and cancer care standards .So, as soon as our team had signed the retainer agreement with him, they began investigating his academic and professional achievements. This helped them make an exhaustive list of his accomplishments, which were later used to write his petition for the USCIS. The list contained some of the following:

• A detailed description of his proposed endeavor was first given to familiarize the adjudicating bench with the merits of his case.
• We tried to show that his research advancing his proposed endeavor is of great importance because it improves our ability to treat many forms of cancer and prostate cancer in particular.
• This is why he also obtained 4 letters recommending his work for the country and the world. Of these recommendations, one had the following passage:

“[Client’s] research has wider applications beyond the research sphere. Cancer is one of the leading causes of death in the United States, with over 600,000 people dying from the disease in 2020 alone. In addition to causing hundreds of thousands of deaths, the economic cost of cancer is exceedingly high… His development of the targeting peptide, which is a low-cost and effective antitumor treatment compatible with existing cancer treatments, is clearly beneficial to this goal. As such, his continued research is undoubtedly relevant to the national interest. The funding his work has received from the National Cancer Institute, the Department of Defense, and the National Institutes of Health further highlights the significance of this research to the United States.”

• Furthermore, due to its clear national importance, his research has also been supported with funding from the National Institutes of Health, National Cancer Institute, NCI Cancer Research Center, National Center for Advancing Translational Sciences, Department of Defense, Rachel Guss and Bob Pomerenk Pancreas Cancer Research Fellowship.
• At the same time, his work has resulted in 4 peer-reviewed journal articles and 2 peer-reviewed abstracts (1 of them first-authored).
• We also noted that these publications have been cited a total of 109 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of molecular biology.

All of these facts helped us indicate successfully that his work was indeed valuable for the United States and thus should be allowed to continue. This won him the approval of the adjudication committee in 6 months only.

We are glad to have worked with him and we wish him all the best in his future endeavors.